Reactivation Risk of Latent Tuberculosis or Inactive Hepatitis B Virus Infection and Effectiveness of Ustekinumab in Chinese Plaque Psoriasis Patients: A 28-Week Retrospective, Observational Study

Figures & data

Table 1 Baseline Demographics and Clinical Characteristics of the Patients

Characteristic	Mean ± SD	Median (IQR)
Age (year)	43.33 ± 14.18	42 (32, 54.5)
Male sex, n/N (%)	55/82 (67.1%)
Weight (kg)	69.07 ± 11.90	70 (60, 76)
BMI (kg/m^2)	24.02 ± 3.32	23.96 (21.77, 26.1)
Disease duration (year)	14.68 ± 9.65	12 (8, 20)
Family history, n/N (%)	36/82 (43.9%)
Prior biologic treatment history, n/N (%)	5/82 (6.1%)
PASI score, 0–72	14.93 ± 12.0	10.6 (5.85, 19.8)
BSA (%)	20.65 ± 18.06	15.5 (6.25, 30.5)
PGA marked or severe (≥4), n/N (%)	19/82 (23.2%)
DLQI score	14.50 ± 7.23	14 (9, 20)
Combined with LTBI, n/N (%)	20/82 (24.4%)
Combined with inactive HBV infection, n/N (%)	21/82 (25.6%)

Abbreviations: BMI, Body Mass Index; PASI, Psoriasis Area Severity Index; BSA, body surface area involvement; PGA, Physicians’ Global Assessment; DLQI, Dermatology life quality index; LTBI, latent tuberculosis infection; HBV, hepatitis B virus; n/N, n, number of each group N, total number.

Table 2 Tuberculosis and Hepatitis B Screening Outcomes at Week 28 of Patients Combined with LTBI or Inactive HBV Infection at Baseline

NO.	Baseline Complication	Tuberculosis Screening Outcome at Week 28			HBV Screening Outcome at Week 28
		Imaging Abnormality^#	T-SPOT	Active TB Symptoms	HBV Serology Screening	HBV DNA	ALT	AST
5	LTBI, HBV carrier	-	+	-	HbsAg^+, HBcAb^+, HBeAb^+	1.44*10^3	N	N
9	HBV carrier	/	/	/	HBsAb^+, HBcAb^+, HBeAb^+	<100	N	N
11	HBV carrier	/	/	/	HBsAb^+, HBcAb^+, HBeAb^+	<100	N	N
18	HBV carrier	/	/	/	HBcAb^+	<100	N	N
28	HBV carrier	/	/	/	HbsAg^+, HBcAb^+, HBeAb^+	<100	N	N
19	LTBI	-	+	-	/	/	/	/
24	LTBI	-	+	-	/	/	/	/
27	LTBI	-	+	-	/	/	/	/
30	LTBI, HBV carrier	-	+	-	HBsAb^+, HBcAb^+, HBeAb^+	<100	N	N
31	HBV carrier	/	/	/	HbsAb^+, HBeAb^+	<100	N	N
32	LTBI, HBV carrier	-	+	-	HBsAb^+, HBeAb^+	<100	N	N
35	LTBI, HBV carrier	-	+	-	HBsAb^+, HBeAb^+	<100	N	N
37	LTBI, HBV carrier	-	+	-	HbsAg^+, HBcAb^+	<100	N	N
38	LTBI	-	+	-	/	/	/	/
43	LTBI	-	+	-	/	/	/	/
44	LTBI	-	+	-	/	/	/	/
47	HBV carrier	/	/	/	HBsAb^+, HBcAb^+	<100	N	N
50	LTBI	-	+	-	/	/	/	/
54	HBV carrier	/	/	/	HBsAb^+, HBcAb^+	<100	N	N
59	LTBI	-	+	-	/	/	/	/
60	HBV carrier	/	/	/	HBsAb^+, HBcAb^+, HBeAb^+	<100	N	N
61	HBV carrier	/	/	/	HBsAb^+, HBcAb^+, HBeAb^+	<100	N	N
63	LTBI	-	+	-	/	/	/	/
64	LTBI	-	+	-	/	/	/	/
68	LTBI	-	+	-	/	/	/	/
69	HBV carrier	/	/	/	HBsAb^+, HBcAb^+	<100	N	N
72	HBV carrier	/	/	/	HBcAb^+	<100	N	N
74	LTBI, HBV carrier	-	+	-	HBcAb^+	<100	N	N
75	HBV carrier	/	/	/	HBsAb^+, HBcAb^+	<100	N	N
76	LTBI	-	+	-	/	/	/	/
77	LTBI	-	+	-	/	/	/	/
78	HBV carrier	/	/	/	HBcAb^+	<100	N	N
79	HBV carrier	/	/	/	HBsAb^+, HBcAb^+	<100	N	N
81	LTBI	-	+	-	/	/	/	/
82	HBV carrier	/	/	/	HBcAb^+	<100	N	N

Notes: ^#Signs of active tuberculosis infection demonstrated by imaging included chest X-ray or CT; -: Negative; +: Positive; N: Normal. Normal range of ALT is defined as 9–50U/L, and Normal range of AST is defined as 14–40U/L; /: Not have been screened because no corresponding complication at baseline.

Abbreviations: LTBI, latent tuberculosis infection; HBV, hepatitis B virus; TB, Tuberculosis; ALT, alanine aminotransferase; AST, aspartate aminotransferase.

Figure 1 PASI 75 and PASI 90 response rate (A) and percentage of PASI improvement (B) during the 28-week treatment period.

Abbreviation: PASI, Psoriasis Area Severity Index.

Figure 2 Change of absolute PASI score (A) and BSA score (B) during the 28-week treatment period. *P<0.001 compared with baseline; ^#P<0.001 compared with week 4; ^‡P<0.001 compared with week 16; ^§P=0.001 compared with week 16.

Abbreviations: PASI, Psoriasis Area Severity Index; BSA, body surface area involvement.

Figure 3 Percentage of patients achieved aPASI≤1, aPASI≤3 and PGA=0 during the 28-week treatment period.

Abbreviations: aPASI, absolute Psoriasis Area Severity Index; PGA, Physicians’ Global Assessment.

Figure 4 (A) Change of DLQI score and (B) percentage of patients achieved DLQI 0/1 during the 28-week treatment period.

Abbreviation: DLQI, Dermatology life quality index.

Data Sharing Statement

The data of this study can be available from Dr Wen-Sheng Lu ([email protected]) for reasonable request.